An INRS research team has identified a new family of enzymes that can make precise cuts in single-stranded DNA. A few years ...

CRCs are the third most common cancer and the second leading cause of cancer deaths in the world. However, SRCC is an ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing their ability to infiltrate solid tumours.

The poster presented data from AUTX-703, a potent, selective and orally bioavailable heterobifunctional degrader of KAT2A/B, an AURIGIN-identified histone acetyltransferase driving small cell lung ...

NEWTON, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and ...

proliferation of prostate cancer cells, and induction of apoptosis. In an AR-expressing patient-derived xenograft mouse model, bavdegalutamide showed substantial AR degradation and greater tumor ...

1Cell and Tumor Biology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, India.

LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of ...

Title: ATG-201, a novel T-cell engager (TCE) effectively depletes B cells with reduced risk of CRS for the treatment of B cell malignancies and B cell related autoimmune diseases ...

Preclinical studies have demonstrated IDE275's (GSK959) potential as a best-in-class WRN inhibitor, inducing single-agent tumor regressions in MSI-H patient-derived xenograft (PDX) and cell line ...